IlluminaILMN
ILMN
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
73% more call options, than puts
Call options by funds: $344M | Put options by funds: $199M
67% more first-time investments, than exits
New positions opened: 142 | Existing positions closed: 85
12% more capital invested
Capital invested by funds: $18.4B [Q3] → $20.6B (+$2.19B) [Q4]
8.68% more ownership
Funds ownership: 88.65% [Q3] → 97.33% (+8.68%) [Q4]
7% more funds holding in top 10
Funds holding in top 10: 14 [Q3] → 15 (+1) [Q4]
5% more funds holding
Funds holding: 792 [Q3] → 834 (+42) [Q4]
16% less repeat investments, than reductions
Existing positions increased: 254 | Existing positions reduced: 302
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$90
15%
upside
Avg. target
$128
64%
upside
High target
$190
143%
upside
9 analyst ratings
4 positive
44%
4 neutral
44%
1 negative
11%
RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target | 64%upside $128 | Outperform Maintained | 12 Mar 2025 |
Stephens & Co. Mason Carrico 18% 1-year accuracy 5 / 28 met price target | 100%upside $156 | Overweight Reiterated | 11 Mar 2025 |
Canaccord Genuity Kyle Mikson 33% 1-year accuracy 9 / 27 met price target | 47%upside $115 | Hold Maintained | 11 Mar 2025 |
Baird Catherine Ramsey 31% 1-year accuracy 5 / 16 met price target | 15%upside $90 | Neutral Maintained | 5 Mar 2025 |
Citigroup Patrick Donnelly 23% 1-year accuracy 7 / 31 met price target | 15%upside $90 | Neutral Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 18 articles about ILMN published over the past 30 days
Positive
CNBC
3 days ago
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
Negative
Investors Business Daily
5 days ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
Positive
Seeking Alpha
5 days ago
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years.
Neutral
PRNewsWire
1 week ago
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Stephen MacMillan to retire from the Board SAN DIEGO , March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board.
Positive
Reuters
1 week ago
Activist investor Keith Meister to join Illumina's board, WSJ reports
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
Positive
WSJ
1 week ago
Activist Investor Meister to Join Illumina's Board
Keith Meister's hedge fund Corvex Management has a 2.5% stake in the gene-sequencing machine maker.
Positive
Zacks Investment Research
1 week ago
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.
Neutral
PRNewsWire
1 week ago
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO , March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development.
Positive
Zacks Investment Research
2 weeks ago
Why Illumina (ILMN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
2 weeks ago
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Charts implemented using Lightweight Charts™